UB Paderborn / Katalog / Suche / in CDI

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

The oncologist (Dayton, Ohio), 2015-07, Vol.20 (7), p.812-822

2015

Link zum Volltext

Verfügbarkeit prüfen

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

The Lancet (British edition), 2016-07, Vol.388 (10043), p.488-497

2016

Link zum Volltext

Verfügbarkeit prüfen

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?

American journal of clinical oncology, 2012-12, Vol.35 (6), p.606-611

2012

Link zum Volltext

Verfügbarkeit prüfen

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e001246

2020

Link zum Volltext

Verfügbarkeit prüfen

Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients

Future oncology (London, England), 2024-03, Vol.20 (10), p.579

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264―272)/HLA-A0201 Complex, in Patients with Advanced Malignancies

Clinical cancer research, 2011-12, Vol.17 (24), p.7765-7775

2011

Link zum Volltext

Verfügbarkeit prüfen

CTIM-17. ADDITIONAL RESULTS FROM A PHASE 1B STUDY OF IGV-001 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v65-v65

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Experimental Studies on the Use of 3,5-Diiodothyropropionic Acid, a Thyroid Hormone Analogue, in Heart Failure

Thyroid (New York, N.Y.), 2002-06, Vol.12 (6), p.527-533

2002

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 Study of Oral TP-0184 for the Treatment of Anemia in Adults with Low- or Intermediate-Risk Myelodysplastic Syndromes

Blood, 2021-11, Vol.138 (Supplement 1), p.1534-1534

2021

Link zum Volltext

Verfügbarkeit prüfen

Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer

Cancer treatment reviews, 2021-06, Vol.97, p.102172-102172, Article 102172

2021

Link zum Volltext

Verfügbarkeit prüfen

TIPS-18 TRIAL IN PROGRESS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2B STUDY TO ASSESS THE SAFETY AND EFFICACY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGONUCLEOTIDE (IMV-001) TARGETING IGF-1R, IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA

Neuro-oncology advances, 2023-08, Vol.5 (Supplement_3), p.iii38-iii38

2023

Link zum Volltext

Verfügbarkeit prüfen

RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v260-v260

2023

Link zum Volltext

Verfügbarkeit prüfen

Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study

The American heart journal, 1999-03, Vol.137 (3), p.494-499

1999

Link zum Volltext

Verfügbarkeit prüfen

Pathophysiologic Correlates of Thromboembolism in Nonvalvular Atrial Fibrillation: II. Dense Spontaneous Echocardiographic Contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] Study)

Journal of the American Society of Echocardiography, 1999-12, Vol.12 (12), p.1088-1096

1999

Link zum Volltext

Verfügbarkeit prüfen

Left ventricular performance and remodeling in rabbits after myocardial infarction : effects of a thyroid hormone analogue

Circulation (New York, N.Y.), 1995-02, Vol.91 (3), p.794-801

1995

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT134: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic (PK), and pharmacodynamic study of oral TP-0184, an activin receptor-like kinase-2 (ALK2) inhibitor, in patients (pts) with advanced solid tumors (ASTs)

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT134-CT134

2022

Link zum Volltext

Verfügbarkeit prüfen

Prevention of Abnormal Sarcoplasmic Reticulum Calcium Transport and Protein Expression in Post-infarction Heart Failure Using 3,5-Diiodothyropropionic Acid (DITPA)

Journal of molecular and cellular cardiology, 2000-11, Vol.32 (11), p.1939-1953

2000

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT171: A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT171-CT171

2023

Link zum Volltext

Verfügbarkeit prüfen

Echocardiographic changes after myocardial infarction in a model of left ventricular diastolic dysfunction

American journal of physiology. Heart and circulatory physiology, 1997-10, Vol.273 (4), p.H2018-H2029

1997

Link zum Volltext

Verfügbarkeit prüfen

DITPA prevents the blunted contraction-frequency relationship in myocytes from infarcted hearts

American journal of physiology. Heart and circulatory physiology, 2000-03, Vol.278 (3), p.H862-H870

2000

Link zum Volltext

Verfügbarkeit prüfen

Increased intraventricular velocities : An unrecognized cause of systolic murmur in adults

Journal of the American College of Cardiology, 1998-11, Vol.32 (6), p.1589-1595

1998

Link zum Volltext

Verfügbarkeit prüfen

Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma

The Lancet (British edition), 2016-06, Vol.388 (10043), p.488-497

2016

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.10501-10501

2015

Link zum Volltext

Verfügbarkeit prüfen

CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS9103-TPS9103

2013

Link zum Volltext

Verfügbarkeit prüfen

A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS9105-TPS9105

2013

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264―272)/HLA-A0201 Complex, in Patients with Advanced Malignancies

CTIM-17. ADDITIONAL RESULTS FROM A PHASE 1B STUDY OF IGV-001 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Clinical and Experimental Studies on the Use of 3,5-Diiodothyropropionic Acid, a Thyroid Hormone Analogue, in Heart Failure

Phase 1/2 Study of Oral TP-0184 for the Treatment of Anemia in Adults with Low- or Intermediate-Risk Myelodysplastic Syndromes

Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer

TIPS-18 TRIAL IN PROGRESS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2B STUDY TO ASSESS THE SAFETY AND EFFICACY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGONUCLEOTIDE (IMV-001) TARGETING IGF-1R, IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA

RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS

Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study

Pathophysiologic Correlates of Thromboembolism in Nonvalvular Atrial Fibrillation: II. Dense Spontaneous Echocardiographic Contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] Study)

Left ventricular performance and remodeling in rabbits after myocardial infarction : effects of a thyroid hormone analogue

Abstract CT134: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic (PK), and pharmacodynamic study of oral TP-0184, an activin receptor-like kinase-2 (ALK2) inhibitor, in patients (pts) with advanced solid tumors (ASTs)

Prevention of Abnormal Sarcoplasmic Reticulum Calcium Transport and Protein Expression in Post-infarction Heart Failure Using 3,5-Diiodothyropropionic Acid (DITPA)

Abstract CT171: A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results

Echocardiographic changes after myocardial infarction in a model of left ventricular diastolic dysfunction

DITPA prevents the blunted contraction-frequency relationship in myocytes from infarcted hearts

Increased intraventricular velocities : An unrecognized cause of systolic murmur in adults

Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS)

CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM)

A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy

Suchergebnisse filtern